AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28296510 — intervention group
Group type: COMPARATOR
Intervention: Follow-up by a general practitioner
Number of subjects: 151
Study 25475196 — intervention group
Group type: EXPERIMENTAL
Intervention: IV magnesium sulfate 1 g just before the procedure
Number of subjects: 122
Study 25475196 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (control group)
Number of subjects: 122
Study 23268365 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% nitroglycerine gel
Number of subjects: 37
Study 23268365 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25% nitroglycerine gel
Number of subjects: 37
Study 23268365 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 37
Study 21991568 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation system
Number of subjects: 32
Study 21991568 — intervention group
Group type: COMPARATOR
Intervention: Control group (without navigation)
Number of subjects: 32
Study 18439116 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 15
Study 16581163 — intervention group
Group type: EXPERIMENTAL
Intervention: Avaxim
Number of subjects: 97
Study 16581163 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaqta
Number of subjects: 97
Study 16581163 — intervention group
Group type: COMPARATOR
Intervention: Intense physical activity during the first month after vaccination
Number of subjects: 97
Study 14561059 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer School Program
Number of subjects: 0
Study 14561059 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Program
Number of subjects: 0
Study 10758784 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐25 (25 micrograms/day E2)
Number of subjects: 156
Study 10758784 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐37.5 (37.5 micrograms/day E2)
Number of subjects: 156
Study 10758784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 8969875 — intervention group
Group type: EXPERIMENTAL
Intervention: 110 Hz TENS
Number of subjects: 80
Study 8969875 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Hz TENS
Number of subjects: 80
Study 8969875 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 8969875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 8969875 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Hz and 50 microseconds TENS
Number of subjects: 80
Study 8969875 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Hz and 200 microseconds TENS
Number of subjects: 80
Study 8969875 — intervention group
Group type: EXPERIMENTAL
Intervention: 110 Hz and 50 microseconds TENS
Number of subjects: 80
Study 8969875 — intervention group
Group type: EXPERIMENTAL
Intervention: 110 Hz and 200 microseconds TENS
Number of subjects: 80
Study 1467110 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural morphine 2.5 mg i.p. and normal saline i.v. (group I)
Number of subjects: 17
Study 1467110 — intervention group
Group type: COMPARATOR
Intervention: Morphine 2.5 mg i.v. and i.p. saline (group II)
Number of subjects: 17
Study 6420025 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 600 mg p.o.
Number of subjects: 8
Study 6420025 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 10 mg IM
Number of subjects: 8
Study 6420025 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 10 mg IM preceded by cimetidine 600 mg p.o.
Number of subjects: 8
Study 6420025 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 600 mg p.o. and Morphine 10 mg IM
Number of subjects: 8
Study 29796016 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 141
Study 29796016 — intervention group
Group type: COMPARATOR
Intervention: Physical training
Number of subjects: 141
Study 29796016 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 141
Study 29796016 — intervention group
Group type: COMPARATOR
Intervention: Social control group
Number of subjects: 141
Study 28065188 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanone-rich orange juice (272.1 mg)
Number of subjects: 28
Study 28065188 — intervention group
Group type: EXPERIMENTAL
Intervention: Homogenised whole orange (452.8 mg)
Number of subjects: 28
Study 28065188 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice (128.9 mg)
Number of subjects: 28
Study 28065188 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic control (0 mg flavanones)
Number of subjects: 28
Study 25327311 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiglinide 10 mg three times a day
Number of subjects: 11
Study 25327311 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 50 mg once a day
Number of subjects: 11
Study 23566649 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg daily)
Number of subjects: 361
Study 19931080 — intervention group
Group type: EXPERIMENTAL
Intervention: DRP/20EE
Number of subjects: 48
Study 19931080 — intervention group
Group type: EXPERIMENTAL
Intervention: DRP/20EE plus metformin (1,500 mg/d)
Number of subjects: 48
Study 19931080 — intervention group
Group type: EXPERIMENTAL
Intervention: DRP/20EE plus CPA (12.5 mg/d, 10 days per cycle)
Number of subjects: 48
Study 18685517 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study 18685517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16630997 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 3029
Study 16630997 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 3029
Study 12401731 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg b.i.d. orally)
Number of subjects: 124
Study 12401731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 10216887 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere®) as second-line chemotherapy
Number of subjects: 0
Study 10216887 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere®)
Number of subjects: 0
Study 10216887 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic corticotherapy
Number of subjects: 0
Study 7565904 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin K administration (group A)
Number of subjects: 152
Study 7565904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin K administration (group B)
Number of subjects: 152
Study 7565904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin K administration (group C)
Number of subjects: 152
Study 7565904 — intervention group
Group type: COMPARATOR
Intervention: Reference population (children aged 1-15 years)
Number of subjects: 152
Study 1980827 — intervention group
Group type: EXPERIMENTAL
Intervention: molindone at pre-established doses equivalent to pre-study neuroleptic
Number of subjects: 18
Study 1980827 — intervention group
Group type: COMPARATOR
Intervention: haloperidol at pre-established doses equivalent to pre-study neuroleptic
Number of subjects: 18
Study 1980827 — intervention group
Group type: EXPERIMENTAL
Intervention: molindone at 200% of pre-study dose
Number of subjects: 18
Study 1980827 — intervention group
Group type: COMPARATOR
Intervention: haloperidol at 200% of pre-study dose
Number of subjects: 18
Study 7326693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 160
Study 7326693 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 160
Study 31814531 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-relevant, physical activity-enhanced behavioral weight loss intervention
Number of subjects: 85
Study 31814531 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral weight loss intervention
Number of subjects: 85
Study 31532802 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-based cognitive behavioral therapy (ICBT) for 14 weeks
Number of subjects: 70
Study 31532802 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 70
Study 29273027 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus bergamia extracts-based formulation (CitriCholess)
Number of subjects: 98
Study 26281160 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid probiotic form based on Enterococcus faecium L3, daily dose of 1.5 x 10(9) CFU for three months
Number of subjects: 29
Study 26281160 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotic)
Number of subjects: 29
Study 26281160 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid probiotic form based on Enterococcus faecium L3
Number of subjects: 29
Study 24806143 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified short-axis out-of-plane (SA-OOP) ultrasound guidance
Number of subjects: 164
Study 24806143 — intervention group
Group type: COMPARATOR
Intervention: Long-axis in-plane (LA-IP) ultrasound guidance
Number of subjects: 164
Study 23095644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention targeting frailty
Number of subjects: 119
Study 23095644 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 119
Study 23095644 — intervention group
Group type: COMPARATOR
Intervention: Intervention and Control
Number of subjects: 119
Study 19448381 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg twice a day with 20 mg esomeprazole once a day
Number of subjects: 132
Study 19448381 — intervention group
Group type: COMPARATOR
Intervention: Placebo with placebo esomeprazole
Number of subjects: 132
Study 19448381 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen in ApoE epsilon4 carriers (n=27)
Number of subjects: 132
Study 19448381 — intervention group
Group type: COMPARATOR
Intervention: Placebo in ApoE epsilon4 carriers (not specified)
Number of subjects: 132
Study 17854445 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL+corticosteroids (ST)
Number of subjects: 430
Study 17854445 — intervention group
Group type: COMPARATOR
Intervention: SRL+CsA+ST
Number of subjects: 430
Study 15352910 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat treatment for 6 months
Number of subjects: 10
Study 11585018 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (single dose) in early luteal phase
Number of subjects: 0
Study 11585018 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (single dose) in mid-luteal phase
Number of subjects: 0
Study 11585018 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone alone or in combination with a prostaglandin
Number of subjects: 0
Study 11585018 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone with prostaglandin
Number of subjects: 0
Study 11585018 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (emergency contraception)
Number of subjects: 0
Study 11585018 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg vs 10 mg)
Number of subjects: 0
Study 10463872 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% brimonidine eye drops
Number of subjects: 10
Study 8830063 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 34
Study 8830063 — intervention group
Group type: COMPARATOR
Intervention: Valproate (VPA)
Number of subjects: 34
Study 8830063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 2142576 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/GSD
Number of subjects: 11
Study 2142576 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/DG
Number of subjects: 11
Study 2142576 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/DG and EE/GSD
Number of subjects: 11
Study 489921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 0.75 mg/kg bw
Number of subjects: 16
Study 489921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1.5 mg/kg bw
Number of subjects: 16
Study 489921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 3.0 mg/kg bw
Number of subjects: 16
Study 489921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 6.0 mg/kg bw
Number of subjects: 16
Study 489921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31972628 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone OAD
Number of subjects: 324
Study 31972628 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine XR
Number of subjects: 324
Study 31306331 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent reproductive coercion
Number of subjects: 550
Study 31306331 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical or sexual adolescent relationship abuse
Number of subjects: 550
Study 31306331 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpartner sexual violence
Number of subjects: 550
Study 31306331 — intervention group
Group type: COMPARATOR
Intervention: Care-seeking behaviors with recent reproductive coercion
Number of subjects: 550
Study 31306331 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing or treatment for sexually transmitted infections
Number of subjects: 550
Study 31306331 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner age and number of sexual partners
Number of subjects: 550
Study 31306331 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraception only
Number of subjects: 550
Study 28090798 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR 20 mg/mL daily
Number of subjects: 729
Study 25614151 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous laser disc decompression (PLDD)
Number of subjects: 115
Study 25614151 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 115
Study 23433939 — intervention group
Group type: EXPERIMENTAL
Intervention: DPA meal
Number of subjects: 0
Study 23433939 — intervention group
Group type: COMPARATOR
Intervention: EPA meal
Number of subjects: 0
Study 23433939 — intervention group
Group type: COMPARATOR
Intervention: Olive oil meal
Number of subjects: 0
Study 20945090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential decision-making process regarding adjuvant therapy options (one at a time)
Number of subjects: 1781
Study 20945090 — intervention group
Group type: COMPARATOR
Intervention: Standard, comprehensive decision process (all at once)
Number of subjects: 1781
Study 20945090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential decision-making process among higher-numeracy participants
Number of subjects: 1781
Study 20945090 — intervention group
Group type: COMPARATOR
Intervention: All options considered simultaneously among lower-numeracy participants
Number of subjects: 1781
Study 20945090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential decision-making process among lower-numeracy participants
Number of subjects: 1781
Study 19756164 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 40 mg/day
Number of subjects: 2306
Study 19756164 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg/day plus HCTZ 12.5 mg/day
Number of subjects: 2306
Study 19756164 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg/day (open-label)
Number of subjects: 2306
Study 17143633 — intervention group
Group type: EXPERIMENTAL
Intervention: ACDF with Cloward procedure (CP)
Number of subjects: 95
Study 17143633 — intervention group
Group type: EXPERIMENTAL
Intervention: ACDF with cervical intervertebral fusion cage (CIFC)
Number of subjects: 95
Study 17143633 — intervention group
Group type: EXPERIMENTAL
Intervention: ACDF (both procedures)
Number of subjects: 95
Study 14667741 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate colposcopy
Number of subjects: 825
Study 14667741 — intervention group
Group type: COMPARATOR
Intervention: Surveillance by repeat HPV testing, cytology, and colposcopy at 12 months
Number of subjects: 825
Study 10826311 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine agents (antiestrogens, progestational drugs, aromatase inhibitors)
Number of subjects: 0
Study 10826311 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 9031926 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic surgery (TCRE)
Number of subjects: 204
Study 9031926 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic surgery (ELA)
Number of subjects: 204
Study 9031926 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 204
Study 1736566 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent ischemia during exercise test (ET) with ST depression
Number of subjects: 740
Study 1736566 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent ischemia during exercise test (ET)
Number of subjects: 740
Study 1736566 — intervention group
Group type: EXPERIMENTAL
Intervention: ST depression combined with pain at ET
Number of subjects: 740
Study 6502506 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate (10 mg) administered intravenously
Number of subjects: 7
Study 6502506 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (300 mg po four times a day)
Number of subjects: 7
Study 3943267 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (12.5, 25, 50, 100 mg)
Number of subjects: 16
Study 3943267 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevantolol (18.75, 37.5, 75, 150 mg)
Number of subjects: 16
Study 3943267 — intervention group
Group type: COMPARATOR
Intervention: Control observations (no drug)
Number of subjects: 16
Study 29762276 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 IU injection of Botulinum toxin A (BoNT‐A)
Number of subjects: 60
Study 29762276 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 60
Study 29762276 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT‐A)
Number of subjects: 60
Study 26908120 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 0
Study 26908120 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 0
Study 24732441 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic cigarettes without nicotine
Number of subjects: 25
Study 24732441 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic cigarettes with nicotine
Number of subjects: 25
Study 24732441 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cigarettes
Number of subjects: 25
Study 24732441 — intervention group
Group type: COMPARATOR
Intervention: Control session (electronic cigarette without liquid)
Number of subjects: 25
Study 22612785 — intervention group
Group type: EXPERIMENTAL
Intervention: Locked continuous single-layer sutures
Number of subjects: 60
Study 22612785 — intervention group
Group type: COMPARATOR
Intervention: Single-layer interrupted sutures
Number of subjects: 60
Study 20074348 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement programme
Number of subjects: 2000
Study 20074348 — intervention group
Group type: COMPARATOR
Intervention: No quality improvement programme (Control)
Number of subjects: 2000
Study 18175773 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 10305
Study 16343234 — intervention group
Group type: EXPERIMENTAL
Intervention: TEC (paclitaxel 175 mg/m(2) followed by carboplatin AUC 5 with epirubicin 75 mg/m(2))
Number of subjects: 887
Study 16343234 — intervention group
Group type: COMPARATOR
Intervention: TC (paclitaxel 175 mg/m(2) followed by carboplatin AUC 5 without epirubicin)
Number of subjects: 887
Study 16343234 — intervention group
Group type: EXPERIMENTAL
Intervention: TEC (with epirubicin)
Number of subjects: 887
Study 16343234 — intervention group
Group type: COMPARATOR
Intervention: TC (without epirubicin)
Number of subjects: 887
Study 16343234 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 887
Study 15600131 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation plus cognitive distraction (PMR/CD)
Number of subjects: 53
Study 15600131 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction and stimulus control (SR/SC)
Number of subjects: 53
Study 15600131 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam (Dalmane) (MED)
Number of subjects: 53
Study 15600131 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene education (SHE)
Number of subjects: 53
Study 11195269 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors (SSRIs) with daily or intermittent dosing
Number of subjects: 0
Study 11195269 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase only SSRI administration
Number of subjects: 0
Study 11195269 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal interventions (suppression of ovulation)
Number of subjects: 0
Study 9421558 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 0
Study 9421558 — intervention group
Group type: COMPARATOR
Intervention: Randomized clinical trials (RCTs)
Number of subjects: 0
Study 2064730 — intervention group
Group type: EXPERIMENTAL
Intervention: l-dopa (300-1000 mg per day) with peripheral decarboxylase inhibitor (benserazide, carbidopa)
Number of subjects: 9
Study 2064730 — intervention group
Group type: COMPARATOR
Intervention: Control persons (n=14, aged 58.0 ± 10.4 years)
Number of subjects: 9
Study 6199470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial irradiation (1,800 rad) with intrathecal methotrexate (RT group)
Number of subjects: 108
Study 6199470 — intervention group
Group type: COMPARATOR
Intervention: Intravenous and intrathecal methotrexate without irradiation (IVIT group)
Number of subjects: 108
Study 31465533 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting pasireotide
Number of subjects: 150
Study 29162321 — intervention group
Group type: EXPERIMENTAL
Intervention: NFC Pendant
Number of subjects: 96
Study 29162321 — intervention group
Group type: EXPERIMENTAL
Intervention: NFC Pendant and Voice
Number of subjects: 96
Study 29162321 — intervention group
Group type: COMPARATOR
Intervention: Control (Sticker)
Number of subjects: 96
Study 28039406 — intervention group
Group type: EXPERIMENTAL
Intervention: PPB
Number of subjects: 38
Study 28039406 — intervention group
Group type: EXPERIMENTAL
Intervention: PL
Number of subjects: 38
Study 28039406 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 38
Study 24267796 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% ALA
Number of subjects: 110
Study 24267796 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% ALA
Number of subjects: 110
Study 24267796 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% ALA
Number of subjects: 110